In Part 1 of a two-part series, Todd Edgar, Alex Grosvenor, and Kellie Rademacher discuss EU biosimilar policies and their impact on the US approach, with a focus on payer coverage. Check back soon for Part 2, highlighting the effects of the NOR-SWITCH trial results and how the EU’s view of biosimilars as therapeutic alternatives, rather than generics, has influenced US policy.
To read the article please click here.